ICGEB awarded for "Most promising vaccine for emerging diseases in India"
At the Vaccine World Summit 2013, held 5-8 March in Pune, India, the Novavax, CPLB and ICGEB collaboration is honored as having the "Most Promising Vaccine for Emerging Diseases in India."
This competitive award recognized the progress made by the International Centre for Genetic Engineering and Biotechnology (ICGEB), Novavax, Inc (Nasdaq:NVAX) and Cadila Pharmaceuticals Ltd. Biologicals (CPLB) to develop a new and effective malaria vaccine. It was one of five inaugural awards honoring achievements in India's vaccine industry.
The ICGEB/Novavax/CPLB collaboration was established in 2012 to combine the advanced vaccine technology of Novavax with the malaria vaccine research capabilities of ICGEB and vaccine manufacturing capability of CPLB. The project is being funded by India's Department of Biotechnology Vaccine Grand Challenge Program and managed by the Malaria Vaccine Development Program, a New Delhi-based nonprofit organization established to support the development of malaria vaccines.
"The technology from Novavax has allowed us to explore a novel delivery platform to develop malaria vaccines and the initial results from pre-clinical studies are exciting" said Professor Virander S. Chauhan, Director, ICGEB New Delhi.
"We thank our industry peers for honoring this important work and congratulate our colleagues in India for their outstanding progress toward the development of an effective malaria vaccine," said Stanley C. Erck, President and CEO of Novavax. "Malaria remains a major public health problem in many parts of the tropical world and we are committed to identifying a safe and effective vaccine that can prevent its spread and devastating effects."